Zytoprotec, an Austria-based company developing dialysis treatments for kidney failure, has raised €2m ($2.7m) from Baxter Ventures, the corporate venturing unit of the eponymous drugs company, as part of a planned €4m series A round.
Norbert Riedel, chief science and innovation officer at Baxter International, will join Zytoprotec’s supervisory board.
In May, Zytoprotec completed its phase I/II clinical trial with its lead product, PD-protec, and said it would be starting phase II and was “in advanced negotiations with a venture…
